Skip to content

Allen & Overy advises Sartorius on the financing of the acquisition of Albumedix

Related people
Neubaum Thomas
Thomas Neubaum

Partner

Frankfurt am Main

View profile →

Dr Mark Hallett

Counsel

Frankfurt am Main

View profile →

Press contacts

For media enquiries relating to this topic, please contact:

Harald Klett
Harald Klett

Manager PR & Communications

Frankfurt am Main

View profile →

23 August 2022

Allen & Overy has advised Sartorius AG (Sartorius), a leading partner of life science research and the biopharmaceutical industry based in Göttingen, on the financing of the acquisition of 100 percent of Albumedix Ltd. (Albumedix) from private investors through its French listed subgroup Sartorius Stedim Biotech. The agreed purchase price amounts to approximately GBP 415 million.

Albumedix, based in Nottingham, United Kingdom, was founded in 1984 and provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. The business has more than 100 employees and is expected to generate revenue of approximately GBP 33 million in 2022 with a significant double-digit EBITDA margin.

Albumedix is an important addition to Sartorius’ advanced therapy solutions and will be part of the Bioprocess Solutions Division. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.

BNP Paribas provides Sartorius with the financing of the purchase price as the sole mandated lead arranger, bookrunner and underwriter.

The Allen & Overy team comprised partner Thomas Neubaum, counsel Dr Mark Hallett and associate Anastasiya-Evangelina Wiegand (all Banking & Finance, Frankfurt).